

Practitioner's Docket No. MPI02-110P1RNM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Shomir Ghosh et al.
Application No.: 10/678,872 Group No.:
Filed: October 3, 2003 Examiner: N/A
For: PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF
INFLAMMATORY DISEASES

Commissioner for Patents

P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

1. Transmitted herewith for this application are:
 - a. This Transmittal (2 pages);
 - b. Transmittal of Supplemental Information Disclosure Statement A (2 pages);
 - c. Supplemental Information Disclosure Statement A (2 pages);
 - d. Form PTO/SB/08A (1 page);
 - e. Reference cited (BU); and
 - f. Return postcard.

STATUS

2. Applicant is other than a small entity.

FEE DEFICIENCY

6. If any additional fee is required, charge Account No. 501668.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)


37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee" Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.


Signature _____
Sean Hunziker/Carolyn Willey

(type or print name of person certifying)

Date: January 23, 2003

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI02-110P1RNM

7. Correspondence Address

Direct all future correspondence to:

Customer Number 30405

OR


Intellectual Property Department
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street
Cambridge, MA 02139

January 23, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By _____


Allan N. Kutzenco
Registration No. 38,945
Attorney for Applicants
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-444-1598
Facsimile - 617-551-8820



Practitioner's Docket No. MPI02-110P1RNM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Shomir Ghosh et al.
Application No.: 10/678,872 Group No.:
Filed: October 3, 2003 Examiner: N/A
For: PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF
INFLAMMATORY DISEASES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT A

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

1. The information disclosure statement submitted herewith is being filed:

Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

(1) a final action under Section 1.113,

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Address"
Mailing Label No. _____

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Date: January 23, 2003

Signature

Sean Hunziker/Carolyn Willey
(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI02-110P1RNM

- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first:

Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

FEE PAYMENT

2. The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

Applicant believes no fee is due in connection with this submission.

Fee due \$0.00

METHOD OF PAYMENT OF FEE

3. Attached is a check in the amount of \$_____.


Charge Account No. 501668 in the amount of \$0.00.


A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

January 23, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By 
Allan N. Kutzenco
Attorney for Applicants
Reg. No. 38,945
40 Landsdowne Street
Cambridge, MA 02139
Telephone: (617) 444-1598
Facsimile - (617) 551-8820



Practitioner's Docket No. MPI02-110P1RNM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Shomir Ghosh et al.
Application No.: 10/678,872 Group No.:
Filed: October 3, 2003 Examiner: N/A
For: PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF
INFLAMMATORY DISEASES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT A

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. [x] Preliminary Statement;
2. [x] Form PTO/SB/08A (substitute for Form PTO-1449);
3. [x] Copy of listed Information item accompanying this Statement (BU)

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

with sufficient postage as first class mail.

37 C.F.R. SECTION 1.10*


as "Express Mail Post Office to Address"
Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: January 23, 2003


Sean Hunziker/Carolyn Willey
(print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI02-110P1RNM

Preliminary Statement

Pursuant to 37 CFR 1.56, 1.97 and 1.98, applicants submit herewith a recently published international patent application, which may be material to the examination of this application.


No representation is made regarding whether the information cited herein is prior art to applicants' claimed invention or whether that information is material to patentability of the claims.

Copies of Listed Information Items Accompanying This Statement

A copy of the item listed in Form PTO/SB/08A (substitute for Form PTO-1449) accompanies this information disclosure statement.

January 23, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By: 

Allan N. Kutzenco
Attorney for Applicants
Reg. No. 38,945
40 Landsdowne Street
Cambridge, MA 02139
Telephone: (617) 444-1598
Facsimile - (617) 551-8820

Please type a plus sign (+) inside this box

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.~~

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/678872
				Filing Date	October 3, 2003
				First Named Inventor	Ghosh, Shomir
				Group Art Unit	
				Examiner Name	N/A
				Attorney Docket Number	MPI02-110P1RNM
Sheet	1	of	1		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.